NSCLC Survival Rises with Checkpoint Blocker Add-On
(MedPage Today) -- Atezolizumab plus standard therapy also slows disease progression
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news
More News: Non-Small Cell Lung Cancer | Primary Care